Navigation Links
Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
Date:6/14/2011

TAIPEI, Taiwan, June 14, 2011 /PRNewswire-Asia/ -- TWi Biotechnology Inc. announced today that the company has enrolled over 50% of the total 240 patients for the Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes. The randomized, double-blind, placebo-controlled, dose-ranging, multi-center study is primarily designed to evaluate the glycated hemoglglobin A1c (HbA1c) lowering effects of AC-201 in patients with Type II Diabetes Mellitus. Meanwhile, the cardiovascular safety profile will be carefully monitored according to U.S. FDA's guidance. In addition to primary objective, by measuring various biomarkers, the company is able to stratify different patient groups in terms of clinical response, so as to develop personalized, preventive or therapeutic strategies.

"The initiation of Phase IIb study is a major milestone for TWi Biotechnology as we continue to demonstrate the potential efficacy of AC-201," stated Dr. M. Sherry Ku, President & CSO of TWi Biotech. "During the previous Phase IIa study, those patients with inadequate blood glucose control by up to three drug combinations of currently available oral anti-diabetic drugs were treated with AC-201 as an add-on therapy. The Phase IIa proof-of-concept study showed a mean reduction of 0.63% for HbA1c (N=56, p<0.05) at the end of 24 weeks treatment period, which is very promising and encouraging. The detailed results of the Phase IIa study will be presented in the American Diabetes Association (ADA) 71st Annual Meeting Scientific Sessions (June 24-28, 2011) in San Diego, California, USA. With the positive Phase IIa results, we are confident to begin enrolling patients for Phase IIb study in March 2011. As of today, we have enrolled more than 50% of the total 240 patients in U.S. and Taiwan. We are expecting to complete patient enrollment by the end of this year. Our plan is to develop AC-201 as an add-on therapy and/or as a mono therapy for Type II Diabetes."

About TWi Biotechnology

TWi Biotechnology, Inc. (www.twipharma.com) is a leading biopharmaceutical company based in Taipei, Taiwan. The company is specializing in in-licensing and developing innovative new drugs for unmet medical needs. With the solid experience in regulatory affairs and clinical development, the company can expedite the development process of drug candidates for worldwide market. The company is building its product pipeline through in-licensing of late pre-clinical stage drug candidates from renowned pharmaceutical companies and research/academic institutions. The company has three active therapeutic candidates to treat Type II Diabetes complications, retinopathy, and cancer.


'/>"/>
SOURCE TWi Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
2. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
3. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
4. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
5. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
8. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
9. Kuvan Receives Positive Opinion From CHMP for European Approval
10. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
11. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 22, 2017 , ... NetDimensions has ... the Aragon Research Globe™ for Corporate Learning, 2017. , Aragon Research defines Leaders ... demand, and effectively perform against those strategies. NetDimensions’ ranking as a Leader due ...
(Date:5/23/2017)... ... May 23, 2017 , ... Bacterial biofilms, surface adherent communities of bacteria ... pathologies ranging from food poisoning and catheter infections to gum disease and the rejection ... of billions of dollars per year, there is currently a paucity of means for ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... ... today that it is exhibiting in booth B2 at the Association for ... May 22-25. , In addition to demonstrating its Cancer Diagnostic Cockpit and ...
(Date:5/18/2017)... ... 18, 2017 , ... Dr. Ralph Mobbs of the Neuro ... Wales Private Hospital. The procedure was performed on a 46-year-old male patient suffering ... prior to undergoing surgery. , The AxioMed viscoelastic disc is a next-generation disc ...
Breaking Biology Technology:
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
Breaking Biology News(10 mins):